To determine if the progression-free survival of patients with High Grade Astrocytoma who are treated with TVB-2640 in combination with bevacizumab is superior to treatment with bevacizumab alone.
To evaluate the safety of TVB-2640 in combination with bevacizumab in patients with High Grade Astrocytoma.
To determine the extent by which TVB-2640 is able to penetrate the blood brain barrier where it might have the opportunity to affect tumor tissue metabolism.
The primary objective of the study is:
To evaluate the effect of the addition of navitoclax to ruxolitinib on spleen volume
The secondary objectives of the study are:
To assess the effect of the addition of navitoclax to ruxolitinib on total symptom score (TSS) as assessed by the Myelofibrosis Symptom Assessment Form (MFSAF) version 4.0 diary
To evaluate the effect of the addition of navitoclax to ruxolitinib on bone marrow fibrosis
To determine the overall response rate (ORR = sum of rates of complete remission [CR] +
partial remission [PR]) associated with the addition of navitoclax to ruxolitinib
To determine the rate of anemia response associated with the addition of navitoclax to
To describe the safety profile and PK profile observed with the addition of navitoclax to
The primary objective of this study is:
to evaluate the efficacy and safety of luspatercept for the treatment of anemia in subjects
with MPN-associated myelofibrosis with and without RBC-transfusion dependence.
To determine in the context of a randomized trial whether the EFS of patients with newly diagnosed high-risk NBL is improved with the addition of 131I-MIBG during Induction, prior to tandem autologous stem cell transplantation (ASCT).